With deals in tow, Roche ends 2019 with five dis­card­ed pro­grams

With sales com­ing in just shy of Wall Street es­ti­mates and prof­it that just beat ex­pec­ta­tions, Roche capped off 2019 on a high hav­ing fi­nal­ly con­sum­mat­ed its ar­du­ous ac­qui­si­tion of Spark Ther­a­peu­tics. That buy­out was marred with no less than 10 de­lays due to reg­u­la­to­ry con­cerns about an­ti­com­pet­i­tive deal­mak­ing. As is the tra­di­tion, the com­pa­ny al­so culled a num­ber of ex­per­i­men­tal drugs across its pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.